Insulcloud

What Insulcloud does

Insulcloud, S.L. is a Spanish health technology company headquartered in Madrid (with offices in Bilbao and Santiago de Compostela) founded in 2015 to develop connected solutions for people living with diabetes. Its core offering is the Insulclock line of Bluetooth-enabled insulin pen caps (CAPs) that attach to disposable insulin pens (FlexTouch, KwikPen, SoloStar) and automatically detect and log injections, monitor insulin storage temperature (alerting outside the 2-30°C range), and synchronize data with a companion mobile application called Diabetes Control – Insulclock 360. Data is consolidated into a web-based ENDO platform for endocrinologists and hospitals that visualizes insulin adherence, glucose (including AGP), time-in-range, and therapeutic compliance. The company also launched InsulCoach, a €29.90/month subscription telehealth and diabetes coaching service that includes monthly video consultations with specialist nurses and chat support, targeted at Spanish residents with diabetes including gestational diabetes patients and pediatric caregivers.

The company monetizes through three revenue streams: (1) hardware sales of Insulclock and Insulclock 3.0 caps at €240 each via the insulcloud.com e-commerce website (with a bundled €99 cap offer for InsulCoach subscribers); (2) recurring InsulCoach subscriptions; and (3) B2B enterprise engagements with hospitals and endocrinology clinics for the ENDO platform and CAP fleet deployments, handled by a dedicated commercial team. Insulcloud pursues a hybrid go-to-market combining direct-to-consumer e-commerce and a clinician field-sales motion. The company is AEMPS-licensed as a medical device manufacturer (license 8410-PS) and certified to ISO 13485 (medical device quality), ISO 27001 (information security), and ENS high level under RD311/2022, holding European patent EP3517153A1 for its universal insulin pen adapter. Funding has been primarily non-dilutive, sourced via EU Horizon 2020 (Project 739148), CDTI NEOTEC, MICIN, ENISA, BEAZ, and EIT, including a ~€1.57M Concentrador Universal project (CPP2021-009139, 2023-2025) for AI-based therapy recommendations developed with Universidad de Girona (MiceLab). All operations remain restricted to Spain for direct sales and delivery.

Key strategic relationships include clinical partnerships with Hospital de Segovia and Hospital Universitario Fundación Jiménez Díaz (Grupo Quirón Salud), an academic research collaboration with Emory University (published randomized study), and disease community outreach with FEDE (Federación Española de Diabetes). Recognitions include the IOT STARS AWARD at Mobile World Congress, Horizon 2020 selection, and PYME Innovadora designation by MICIN. The company operates without disclosed external venture or private equity investors and uses wholly-owned subsidiaries Insulcloud Delivery S.L.U. and Insulcloud Factory S.L.U. for logistics and manufacturing.

Name

Insulcloud

Legal name

Insulcloud, S.L.

Website

https://insulcloud.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Insulcloud is a Spanish health-tech company that develops Bluetooth-connected insulin pen caps (Insulclock), a diabetes management mobile app, and the ENDO clinician platform, serving diabetes patients, caregivers, and healthcare providers exclusively in Spain.

Ownership category

akta.pro rank

Product category

Connected Diabetes Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (5132)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Smart Insulin Pens & Connected Pen Caps (HLAHAHAD)

akta.pro secondary industries

Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Connected insulin pen
• Diabetes management app
• Remote patient monitoring
• Medical device telemetry
• Telehealth diabetes coaching

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Hardware Sales - Insulclock CAPs: Sale of Insulclock and Insulclock 3.0 intelligent insulin pen caps (CAPs). Each CAP is priced at €240 including VAT. These are one-time hardware purchases compatible with specific insulin pen brands (FlexTouch, KwikPen, SoloStar).
2. Subscription - InsulCoach: Monthly subscription service at €29.90/month providing teleconsultations with diabetes experts, chat support with response within 24 business hours, and access to educational guides and videos. Initial subscription period is 90 days with automatic renewal.
3. Bundled Hardware with Subscription: Insulclock CAP offered at discounted price of €99 (instead of €240 regular price) as add-on for InsulCoach subscribers, creating bundled hardware + subscription revenue opportunity.
4. Professional Platform - ENDO: Healthcare professionals access the ENDO platform for patient monitoring. Revenue model not explicitly disclosed but implied through B2B sales motion targeting hospitals and clinics.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Insulcloud designs, manufactures, and sells a connected diabetes-management ecosystem built around Bluetooth-enabled smart insulin pen caps (Insulclock and Insulclock 3.0) that attach to disposable insulin pens to automatically record injections, monitor insulin temperature, and synchronize data with the Diabetes Control – Insulclock 360 mobile app. The company complements this hardware with the ENDO web platform for healthcare professionals and the InsulCoach subscription service offering monthly teleconsultations, chat support, and educational content for diabetes patients.

Product overview

Insulcloud is a Spanish health technology company that has developed the Sistema Insulcloud 360, an integrated diabetes management ecosystem. The system consists of three core components: (1) Insulclock/Insulclock 3.0 smart insulin pen caps that attach to disposable insulin pens to record injections and monitor temperature; (2) the Diabetes Control mobile app that aggregates insulin data, glucose readings, exercise, and food intake; and (3) the ENDO professional platform for healthcare providers. The company also offers InsulCoach, a subscription telehealth service for diabetes coaching. The Insulclock devices are priced at €240 each and are available in versions compatible with FlexTouch, KwikPen, and SoloStar insulin pens.

Differentiator

Problem solved

Functional benefit

Brands

• Insulclock: Smart insulin pen cap device that converts standard disposable insulin pens into intelligent tracking devices with Bluetooth connectivity, temperature monitoring, and automatic injection logging.
• Insulclock 3.0
• Diabetes Control - Insulclock 360
• ENDO Platform
• InsulCoach

Products and services

• Insulclock smart insulin pen cap Bluetooth-enabled smart cap designed for FlexTouch and KwikPen disposable insulin pens; automatically records the date, time, and ambient temperature of each injection and detects purging to confirm correct injection technique, syncing data wirelessly to the Diabetes Control – Insulclock 360 mobile app for diabetes patients.
• Insulclock 3.0 smart insulin pen cap Bluetooth-enabled smart cap designed specifically for SoloStar disposable insulin pens (Lantus, Toujeo), providing automatic injection recording, insulin temperature monitoring with visual alerts when outside the 2°C–30°C safe range, and up to 1-year battery life on a CR1632 cell with no charging required.
• Diabetes Control – Insulclock 360 mobile application Companion mobile app (iOS and Android) that aggregates insulin data from Insulclock CAPs with blood glucose readings from glucose meters/sensors, exercise activity from fitness bands, and manual meal/carbohydrate logs; provides programmable reminder alarms, generates downloadable diabetes-management reports, and lets patients share information with their endocrinologist.
• ENDO professional platform Web-based platform for endocrinologists, diabetologists, diabetes nurses, and hospitals that delivers real-time monitoring of patient insulin administration, glucose and AGP trends, time-in-range analytics, and therapeutic compliance, with integration of clinical history to streamline patient care.
• InsulCoach diabetes coaching subscription Monthly subscription service for Spanish-resident diabetes patients that delivers one 40-minute video consultation per month with a specialist diabetes nurse, chat support with responses within 24 business hours, and access to educational guides and videos on diabetes self-management.

Quantifiable outcome

• Up to 50% reduction in preventable hypoglycemic events with expert coaching
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Hospital de SegoviacoreStrategic or Co-development PartnerClinical collaboration with Hospital de Segovia for integration of Insulcloud system into diabetes patient care. The hospital participates in diabetes management programs using Insulclock CAP devices and ENDO platform for patient monitoring.
• Fundación Jiménez Díaz (Grupo Quirón Salud)coreStrategic or Co-development PartnerIntegration of Insulclock system in the Hospital Universitario Fundación Jiménez Díaz, part of the Quirón Salud group. Demonstrates adoption of Insulcloud technology in major private hospital network.
• DHLminorOthersDHL is the logistics operator used for delivery of Insulclock products to customers in Spain.
• HIRUSEC S.L.minorOthersCloud hosting provider for Insulcloud customer data and application infrastructure. Located at Paseo Ubarburu 7 Trasera 4C, 20014 San Sebastián (Gipuzkoa), Spain.
• BEAZminorStrategic or Co-development PartnerBEAZ (Bizkaia Agency for Economic Development) provides regional innovation support for Insulcloud as a Basque technology company.
• FEDE (Federación Española de Diabetes)minorStrategic or Co-development PartnerSpanish Diabetes Federation collaboration supporting diabetes patient community outreach and awareness.
• Emory University School of MedicineminorStrategic or Co-development PartnerAcademic partnership for randomized clinical study evaluating Insulclock efficacy in Type 2 diabetes patients. Published research demonstrates clinical validation.
• Universidad de Girona (MiceLab)minorStrategic or Co-development PartnerResearch collaboration as part of the Concentrador Universal project (CPP2021-009139) for AI-based recommendation systems for diabetes management.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Medtronic Diabetes: Medtronic offers the MiniMed 780G AID system and the InPen smart insulin pen (acquired from Companion Medical). Medtronic directly competes with Insulcloud in the connected pen space while dominating the hospital endocrinology procurement channel that Insulcloud is pursuing.
• Abbott Diabetes Care: Abbott's FreeStyle Libre dominates the consumer CGM category and has been expanding into insulin dose decision support features. Abbott represents the primary ecosystem competitor for HCP attention and patient diabetes data ownership.
• Ypsomed: Ypsomed manufactures connected insulin pen injection systems (YpsoPen) and the mylife Loop AID ecosystem. Ypsomed competes in the same connected pen space as Insulcloud's CAP and offers an integrated pump-and-pen alternative for European diabetes patients.
• Novo Nordisk: Novo Nordisk's NovoPen 6 and NovoPen Echo Plus are connected, reusable insulin pens that natively record and transmit dose data. As the dominant insulin pen manufacturer, Novo Nordisk is both a potential competitor and natural partner/distribution channel for Insulcloud's CAP technology.
• Dexcom: Dexcom is the leading CGM manufacturer globally and has expanded into broader diabetes management platforms (Dexcom Clarity, integrations with pumps and digital health apps). Dexcom is both a potential integration partner for Insulcloud and a competitor pulling HCP mindshare toward CGM-centric ecosystems.

Direct peers

• Emperra GmbH: Germany-based Emperra developed the Esysta smart insulin pen, the European counterpart to Insulcloud's CAP. Both attach to disposable pens to automatically record injections, transmit data to a cloud platform, and integrate with HCP-facing dashboards for diabetes therapy management.
• Bigfoot Biomedical: Bigfoot Unity was the most direct US-based competitor with a smart insulin pen cap system that connected disposable insulin pens to CGM data and provided dose guidance. Both companies built integrated hardware-plus-app-plus-clinician-platform ecosystems targeting disposable pen users with Type 1 and Type 2 diabetes.

Emerging players

• mySugr (Roche Diabetes Care): mySugr is one of the most established diabetes self-management apps globally, owned by Roche Diabetes Care. Both mySugr and Insulcloud's Diabetes Control app aggregate glucose, insulin, meal, and activity data, with mySugr representing the consumer-scale incumbent Insulcloud must differentiate against in European markets.
• Tidepool: Tidepool is a US-based nonprofit providing a diabetes data platform (Tidepool Loop, Tidepool Uploader) that aggregates data from multiple pumps, CGMs, and insulin pens for clinician and patient use. Tidepool represents the open-platform alternative to Insulcloud's proprietary ENDO platform for hospital diabetes data integration.
• Diabeloop: French company Diabeloop develops an AID/closed-loop system (DBLG1) integrating CGM and pump data with an AI algorithm for automated insulin delivery. While Diabeloop targets pump users rather than pen users, both companies are European diabetes digital health players competing for the same hospital endocrinology customers and HCP workflow integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/insulcloud
• YouTubeyoutube.com/%40insulcloud
• Facebookfacebook.com/insulcloud
• LinkedInlinkedin.com/company/insulcloud/posts/?feedView=all
• Instagraminstagram.com/insulcloud

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insulcloud